MX374129B - Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos. - Google Patents

Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos.

Info

Publication number
MX374129B
MX374129B MX2015015409A MX2015015409A MX374129B MX 374129 B MX374129 B MX 374129B MX 2015015409 A MX2015015409 A MX 2015015409A MX 2015015409 A MX2015015409 A MX 2015015409A MX 374129 B MX374129 B MX 374129B
Authority
MX
Mexico
Prior art keywords
erythrocytes
loaded
substances
preparation
pharmaceutical interest
Prior art date
Application number
MX2015015409A
Other languages
English (en)
Other versions
MX2015015409A (es
Inventor
Giovanni Capogrossi
Giovanni Mambrini
Luca Benatti
Marco Mandolini
Original Assignee
Erydel Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000280A external-priority patent/ITRM20130280A1/it
Priority claimed from IT000610A external-priority patent/ITRM20130610A1/it
Application filed by Erydel Spa filed Critical Erydel Spa
Publication of MX2015015409A publication Critical patent/MX2015015409A/es
Publication of MX374129B publication Critical patent/MX374129B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01001—Hexokinase (2.7.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)

Abstract

La presente invención se refiere a un proceso para preparar eritrocitos cargados con una o más sustancias de interés farmacéutico. La presente invención también se dirige a eritrocitos cargados de este modo obtenidos y composiciones farmacéuticas que comprenden tal población de eritrocitos cargados así como también aplicaciones terapéuticas de los mismos, en particular en el tratamiento de Ataxia telangiectasia.
MX2015015409A 2013-05-10 2014-05-09 Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos. MX374129B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT000280A ITRM20130280A1 (it) 2013-05-10 2013-05-10 Procedimento per la preparazione di eritrociti caricati con una o più sostanze di interesse farmaceutico.
IT000610A ITRM20130610A1 (it) 2013-11-05 2013-11-05 Eritrociti caricati con una o più sostanze di interesse farmaceutico
PCT/IB2014/061338 WO2014181309A1 (en) 2013-05-10 2014-05-09 Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes

Publications (2)

Publication Number Publication Date
MX2015015409A MX2015015409A (es) 2016-06-02
MX374129B true MX374129B (es) 2025-03-05

Family

ID=50981593

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015409A MX374129B (es) 2013-05-10 2014-05-09 Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos.

Country Status (19)

Country Link
US (3) US10849858B2 (es)
EP (2) EP4338803A3 (es)
JP (1) JP6367314B2 (es)
KR (1) KR102223080B1 (es)
CN (1) CN105228596B (es)
AU (1) AU2014264205B2 (es)
BR (1) BR112015028278B1 (es)
CA (1) CA2911976C (es)
CR (1) CR20150604A (es)
ES (1) ES2950419T3 (es)
IL (1) IL242503B (es)
MX (1) MX374129B (es)
PH (1) PH12015502535B1 (es)
PL (1) PL2994117T3 (es)
PT (1) PT2994117T (es)
RU (1) RU2670070C2 (es)
SA (1) SA515370122B1 (es)
SG (1) SG11201509252QA (es)
WO (1) WO2014181309A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2994117T3 (pl) 2013-05-10 2023-10-16 Erydel S.P.A. Sposób wytwarzania erytrocytów obciążonych jedną lub większą liczbą substancji będących przedmiotem zainteresowania pod względem farmaceutycznym oraz tak otrzymane erytrocyty
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
WO2015153102A1 (en) 2014-04-01 2015-10-08 Rubius Therapeutics, Inc. Methods and compositions for immunomodulation
US11243218B2 (en) 2015-10-07 2022-02-08 Sangui Bio Pty Ltd. Blood preparation and profiling
CN108883133A (zh) * 2015-12-22 2018-11-23 善威生物私人有限公司 使用红细胞的治疗方法
KR101671361B1 (ko) * 2016-08-08 2016-11-01 에스씨엠생명과학 주식회사 TYMP(thymidine phosphorylase) 단백질을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물
AU2017379367B2 (en) 2016-12-20 2023-12-07 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors
US20210403571A1 (en) 2018-11-15 2021-12-30 Erytech Pharma Synergistic combinations of methionine depletion agents and immune checkpoint modulators
CN109453137A (zh) * 2018-12-07 2019-03-12 上海交通大学 一种活红细胞载倍他米松磷酸钠的缓释制剂及其制备方法与应用
CN113008653A (zh) * 2019-12-20 2021-06-22 深圳市帝迈生物技术有限公司 稀释液、血细胞分析仪、血细胞分析仪用试剂以及试剂盒
CA3178252A1 (en) 2020-05-11 2021-11-18 Erytech Pharma Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof
CN111658772B (zh) * 2020-07-22 2022-06-03 南通大学 一种自然光诱导控释药物及其制备方法与应用
US20250340852A1 (en) 2021-05-27 2025-11-06 Erydel S.P.A. Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine
WO2023027613A1 (ru) * 2021-08-27 2023-03-02 Общество С Ограниченной Ответственностью "Рбк-Фармэко" Устройство и способ для включения биологически активных компонентов в эритроциты способом проточного диализа
CN114469865B (zh) * 2022-03-17 2023-09-22 中国医学科学院输血研究所 一种与血细胞膜结合的脂质体药物载体及其制备方法和用途
IT202300026244A1 (it) 2023-12-07 2025-06-07 Univerista Degli Studi Di Urbino Carlo Bo Vescicole extracellulari derivate da globuli rossi caricate con molecole di carico per applicazioni terapeutiche e metodo di produzione delle stesse
WO2025158249A1 (en) * 2024-01-25 2025-07-31 Quince Therapeutics, Inc. Intra-erythrocyte dexamethasone for treatment of ataxia-telangiectasia

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327710A (en) 1980-06-18 1982-05-04 The United States Of America As Represented By The Secretary Of Agriculture Process for encapsulating additives in resealed erythrocytes for disseminating chemicals via the circulatory system
SU1807595A1 (ru) * 1989-10-16 1996-08-10 Целиноградский государственный медицинский институт Минздрава КазССР Средство для лечения отравлений ртутью
EP0690671B1 (en) * 1993-03-23 2004-08-04 Cbr Laboratories, Inc. Method and apparatus for encapsulation of biologically-active substances in cells
EP0882448B1 (en) * 1997-05-05 2005-01-12 DIDECO S.r.l. Method of encapsulating biologically active agents within erythrocytes and apparatus therefor
GB0002856D0 (en) * 2000-02-08 2000-03-29 Gendel Limited Ultrasound sensitisation
KR100478791B1 (ko) * 2002-07-11 2005-03-24 오유경 유전자 수송체로서의 생체 적합성 혈구 세포
FR2873925B1 (fr) * 2004-08-05 2006-10-13 Erytech Pharma Soc Par Actions Procede et dispositif de lyse-rescellement pour l'incorporation de principe actif notamment asparaginase ou inositol hexaphosphate, dans des erythrocytes
ITBO20100256A1 (it) * 2010-04-26 2011-10-27 Erydel Spa Metodo per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti
IT1399590B1 (it) 2010-04-26 2013-04-26 Erydel Spa Apparato e kit per incapsulare almeno un composto ad uso terapeutico e/o diagnostico all'interno di eritrociti
PL2994117T3 (pl) 2013-05-10 2023-10-16 Erydel S.P.A. Sposób wytwarzania erytrocytów obciążonych jedną lub większą liczbą substancji będących przedmiotem zainteresowania pod względem farmaceutycznym oraz tak otrzymane erytrocyty

Also Published As

Publication number Publication date
CN105228596B (zh) 2018-08-24
US20160051482A1 (en) 2016-02-25
BR112015028278B1 (pt) 2022-12-20
EP4338803A2 (en) 2024-03-20
AU2014264205B2 (en) 2018-08-30
SA515370122B1 (ar) 2016-11-08
MX2015015409A (es) 2016-06-02
US10849858B2 (en) 2020-12-01
US12311059B2 (en) 2025-05-27
CA2911976C (en) 2021-01-19
KR102223080B1 (ko) 2021-03-04
PH12015502535B1 (en) 2020-01-29
ES2950419T3 (es) 2023-10-09
CN105228596A (zh) 2016-01-06
PT2994117T (pt) 2023-07-14
US20210283063A1 (en) 2021-09-16
PL2994117T3 (pl) 2023-10-16
CR20150604A (es) 2016-03-09
PH12015502535A1 (en) 2016-02-22
RU2015152801A (ru) 2017-06-16
AU2014264205A1 (en) 2015-11-12
US20250255826A1 (en) 2025-08-14
EP2994117B1 (en) 2023-06-07
IL242503B (en) 2020-08-31
SG11201509252QA (en) 2015-12-30
JP2016518402A (ja) 2016-06-23
EP4338803A3 (en) 2024-10-09
EP2994117A1 (en) 2016-03-16
WO2014181309A1 (en) 2014-11-13
CA2911976A1 (en) 2014-11-13
KR20160005781A (ko) 2016-01-15
JP6367314B2 (ja) 2018-08-01
BR112015028278A2 (pt) 2017-07-25
RU2670070C2 (ru) 2018-10-17

Similar Documents

Publication Publication Date Title
MX374129B (es) Proceso para la preparación de eritrocitos cargados con una o más sustancias de interés farmacéutico y eritrocitos así obtenidos.
EA201890204A1 (ru) Антибактериальные соединения
EA201990043A1 (ru) Антибактериальные соединения
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2016000508A1 (es) Compuestos derivados de (2-metil-3-fenilfenil)metoxi sustituidos, inhibidores de la interacción pd-1/proteína pd-l1/proteína; composición farmacéutica que los comprende; y su uso para tratar una enfermedad infecciosa o cáncer.
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
HUE049341T2 (hu) Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201791007A3 (ru) Соединения и их применения для модуляции гемоглобина
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201290836A1 (ru) Связанные бис-арильные арилтриазолоны и их применение
EA201591427A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EA201591432A1 (ru) Соединения и их применения для модуляции гемоглобина
MX2015009058A (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
EA201591618A1 (ru) Замещенные имидазопиридазины
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591925A1 (ru) Терапевтические композиции и их применение

Legal Events

Date Code Title Description
FG Grant or registration